Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
暂无分享,去创建一个
R. Schilsky | R. Pazdur | M. Thirlwell | W. West | A. Wong | B. Colwell | W. Bell | R. Ansari | J. Levin | B. Yates | P. McGuirt | Robin L White | P. Mcguirt